Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06994416 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Novel Fluorescent Ductal Needle for Localization and Sampling of High-risk Breast Micro Lesions

StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoing Show 4 more changesShow less
    • Study completion pushed from May 31, 2026 to Dec 31, 2026
    • Eligibility criteria expanded, about 10 words
    • Site details revised
    • Publications: details revised at 1 of 1 entry
  2. Eligibility criteria shortened, about 10 wordsv4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v3
  4. Study title shortened, about 7 wordsv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This retrospective cohort study investigates the differences in the reliability of rapid pathology compared to postoperative pathology when utilizing a novel fluorescent localization needle equipped with a controllable shedding quantum dot chiral nanofluorescent coating, in contrast to traditional localization techniques for breast duct lesions. The primary goal is to evaluate the clinical effectiveness of this innovative fluorescent localization needle in facilitating accurate pathological diagnoses of micro lesions situated within breast ducts.
Trial Details
NCT Number NCT06994416
Lead Sponsor The Fourth Affiliated Hospital of China Medical University
Conditions
(from sponsor)		 Mammary Tumor, Nipple Discharge
Related terms Breast Neoplasms, Galactorrhea
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov